Literature DB >> 3457207

Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma.

M R Young, E Wheeler, M Newby.   

Abstract

The natural killer (NK) cell cytotoxic capacity of C57BL/6 mice with implantation of Lewis lung carcinoma (LLC) was quantitated during tumor growth. The NK activity became suppressed at 1 week of tumor growth and remained suppressed. The mechanisms for the suppression during the first 3 weeks of tumor growth included secretion of prostaglandin E2 (PGE2) by both the LLC tumor and host macrophages. With tumor growth, plasma PGE2 concentrations progressively increased. Oral administration of indomethacin to tumor-bearing mice prevented the rise in serum PGE2 concentrations and the suppression of NK activity. Cultured LLC cells and splenic macrophages isolated from mice during the first 3 weeks of tumor growth secreted increased amounts of PGE2. Macrophages from tumor-bearer spleen cells were shown to suppress NK activity. Depletion of these macrophages restored the NK activity, and addition of these macrophages to normal spleen cells resulted in an indomethacin-sensitive suppression of the NK response. The mechanisms of suppression in mice bearing large tumors were different than those observed with smaller tumors. With a large tumor burden, the plasma PGE2 concentrations declined. Indomethacin treatment did not prevent the suppression of NK activity, and depletion of splenic macrophages did not restore NK cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3457207     DOI: 10.1093/jnci/76.4.745

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.

Authors:  M R Young; M A Wright; M Coogan; M E Young; J Bagash
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 2.  COX-2 and PGE2-dependent immunomodulation in breast cancer.

Authors:  Edward P Chen; Emer M Smyth
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-08-31       Impact factor: 3.072

3.  NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22-secreting CD11b+CD11c+ cells.

Authors:  Adam W Mailloux; Anna-Maria A Clark; M Rita I Young
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

4.  Role of macrophages in the host response to Lewis lung peritoneal carcinomatosis.

Authors:  M W Barth; P S Morahan
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 5.  Eicosanoids and the immunology of cancer.

Authors:  M R Young
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

6.  Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.

Authors:  T Reissmann; R Voegeli; J Pohl; P Hilgard
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Potential role of natural killer cells in controlling tumorigenesis by human T-cell leukemia viruses.

Authors:  G Feuer; S A Stewart; S M Baird; F Lee; R Feuer; I S Chen
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

8.  Effect of combined administration of a synthetic low-toxicity lipid A derivative, DT-5461a, and indomethacin in various experimental tumor models of colon 26 carcinoma in mice.

Authors:  T Jimbo; T Akimoto; A Tohgo
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

9.  Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.

Authors:  B A Teicher; T T Korbut; K Menon; S A Holden; G Ara
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Suppressor cells in the effector phase of autologous cytotoxic reactions in cancer patients.

Authors:  M Eura; T Maehara; T Ikawa; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.